Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Review, H1 2016

Global Markets Direct’s, ‘Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Review, H1 2016’, provides in depth analysis on Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted pipeline therapeutics.

The report provides comprehensive information on the Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB)

The report reviews Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics and enlists all their major and minor projects

The report assesses Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Affichem SA

Bristol-Myers Squibb Company

Vitae Pharmaceuticals, Inc.

Affichem SA

Bristol-Myers Squibb Company

Vitae Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Oxysterols Receptor ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) Overview 6

Therapeutics Development 7

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Stage of Development 7

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Therapy Area 8

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Indication 9

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Companies 12

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Products under Development by Universities/Institutes 14

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Therapeutics Assessment 16

Assessment by Monotherapy/Combination Products 16

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Companies Involved in Therapeutics Development 21

Affichem SA 21

Bristol-Myers Squibb Company 22

Vitae Pharmaceuticals, Inc. 23

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Drug Profiles 24

AF-122 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

BMS-779788 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

SR-9238 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

VTP-38543 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

VTP-4 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Dormant Projects 29

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Discontinued Products 30

Oxysterols Receptor LXR-Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily 1 Group H Member 2 or NR1H2 or LXRB) - Featured News & Press Releases 31

Dec 29, 2015: Vitae Pharmaceuticals Doses First Patients in Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis 31

Dec 10, 2015: Vitae Pharmaceuticals Opens Phase 2a Proof-of-Concept Trial of VTP-38543 in Atopic Dermatitis Patients 31

Apr 03, 2015: AFFICHEM announces the presentation of an oral communication at the 35th Annual Meeting of the French Society of Hematology in Paris 32

Dec 06, 2014: AFFICHEM announces the presentation of a poster at the 56th Annual Meeting of the American Society of Hematology in San Francisco 32

Dec 19, 2012: Scripps Florida Scientists Develop New Compound that Reverses Fatty Liver Disease 32

Sep 06, 2012: Vitae Pharma Announces Promising Data On Atherosclerotic Drug VTP-4 At Frontiers In Lipid Biology Conference 33

Nov 29, 2007: Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Achievement Of Liver X Receptor Agonist Development Milestone 34

Dec 06, 2005: Exelixis And Bristol-Myers Squibb Signs New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments 34

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of ...

List of Tables

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Comparative Analysis by Late Stage Development, H1 2016 10

Comparative Analysis by Early Stage Products, H1 2016 11

Number of Products under Development by Companies, H1 2016 12

Products under Development by Companies, H1 2016 13

Number of Products under Investigation by Universities/Institutes, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Assessment by Monotherapy/Combination Products, H1 2016 16

Number of Products by Stage and Mechanism of Action, H1 2016 17

Number of Products by Stage and Route of Administration, H1 2016 19

Number of Products by Stage and Molecule Type, H1 2016 20

Pipeline by Affichem SA, H1 2016 21

Pipeline by Bristol-Myers Squibb Company, H1 2016 22

Pipeline by Vitae Pharmaceuticals, Inc., H1 2016 23

Dormant Projects, H1 2016 29

Discontinued Products, H1 2016 30

List of Figures

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of ...

List of Figures

Number of Products under Development for, H1 2016 7

Number of Products under Development by Therapy Area, H1 2016 8

Number of Products under Development by Indication, H1 2016 9

Assessment by Monotherapy/Combination Products, H1 2016 16

Number of Products by Stage and Mechanism of Actions, H1 2016 17

Number of Products by Routes of Administration, H1 2016 18

Number of Products by Stage and Routes of Administration, H1 2016 18

Number of Products by Stage and Molecule Type, H1 2016 20

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports